Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults
Identifieur interne : 000975 ( Pmc/Corpus ); précédent : 000974; suivant : 000976Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults
Auteurs : Joon Young Song ; Hee Jin Cheong ; Ji Yun Noh ; Tae Un Yang ; Yu Bin Seo ; Kyung-Wook Hong ; In Seon Kim ; Won Suk Choi ; Woo Joo KimSource :
- Clinical and Experimental Vaccine Research [ 2287-3651 ] ; 2013.
Abstract
To prepare for vaccine shortages under an influenza pandemic, several antigen-sparing strategies have been investigated. This study was aimed to evaluate the immunogenicity of influenza vaccine at reduced intradermal and full intramuscular dose.
We compared the effect of one-fifth and one-half intradermal doses to the full intramuscular dose on immunogenicity in healthy young adults, using a commercial influenza vaccine. A hemagglutination inhibition assay was used to compare the immunogenicity of the vaccination methods.
The one-fifth intradermal dose (3 µg hemagglutinin antigen, HA) was given to 30 participants, the one-half intradermal dose (7.5 µg HA) was given to 30, and the full intramuscular dose (15 µg HA) was given to 32. No significant differences among injection routes and dosages were seen for seroprotection rate, seroconversion rate, or geometric mean titer (GMT) fold-increase for A/H1N1, A/H3N2, and B at around 4 weeks from vaccination. Although GMT for influenza B was significantly lower at six months for the one-fifth intradermal vaccination compared to the full-dose intramuscular vaccination (32.8 vs. 63.2, p=0.048), all three groups met the Evaluation of Medicinal Products (EMA) immunogenicity criteria through 1 to 6 months.
Intradermal administration of a one-fifth dose of influenza vaccine elicited antibody responses comparable to the intradermal one-half dose and a conventional intramuscular vaccination at 1 month post-vaccination. The immunogenicity of the one-fifth intradermal dose was sufficient to meet the requirement for the EMA criteria at six months after influenza vaccination.
Url:
DOI: 10.7774/cevr.2013.2.2.115
PubMed: 23858402
PubMed Central: 3710919
Links to Exploration step
PMC:3710919Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults</title><author><name sortKey="Song, Joon Young" sort="Song, Joon Young" uniqKey="Song J" first="Joon Young" last="Song">Joon Young Song</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Cheong, Hee Jin" sort="Cheong, Hee Jin" uniqKey="Cheong H" first="Hee Jin" last="Cheong">Hee Jin Cheong</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Noh, Ji Yun" sort="Noh, Ji Yun" uniqKey="Noh J" first="Ji Yun" last="Noh">Ji Yun Noh</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Yang, Tae Un" sort="Yang, Tae Un" uniqKey="Yang T" first="Tae Un" last="Yang">Tae Un Yang</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Seo, Yu Bin" sort="Seo, Yu Bin" uniqKey="Seo Y" first="Yu Bin" last="Seo">Yu Bin Seo</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Hong, Kyung Wook" sort="Hong, Kyung Wook" uniqKey="Hong K" first="Kyung-Wook" last="Hong">Kyung-Wook Hong</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Kim, In Seon" sort="Kim, In Seon" uniqKey="Kim I" first="In Seon" last="Kim">In Seon Kim</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Choi, Won Suk" sort="Choi, Won Suk" uniqKey="Choi W" first="Won Suk" last="Choi">Won Suk Choi</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Kim, Woo Joo" sort="Kim, Woo Joo" uniqKey="Kim W" first="Woo Joo" last="Kim">Woo Joo Kim</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23858402</idno><idno type="pmc">3710919</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710919</idno><idno type="RBID">PMC:3710919</idno><idno type="doi">10.7774/cevr.2013.2.2.115</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000975</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000975</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults</title><author><name sortKey="Song, Joon Young" sort="Song, Joon Young" uniqKey="Song J" first="Joon Young" last="Song">Joon Young Song</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Cheong, Hee Jin" sort="Cheong, Hee Jin" uniqKey="Cheong H" first="Hee Jin" last="Cheong">Hee Jin Cheong</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Noh, Ji Yun" sort="Noh, Ji Yun" uniqKey="Noh J" first="Ji Yun" last="Noh">Ji Yun Noh</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Yang, Tae Un" sort="Yang, Tae Un" uniqKey="Yang T" first="Tae Un" last="Yang">Tae Un Yang</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Seo, Yu Bin" sort="Seo, Yu Bin" uniqKey="Seo Y" first="Yu Bin" last="Seo">Yu Bin Seo</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Hong, Kyung Wook" sort="Hong, Kyung Wook" uniqKey="Hong K" first="Kyung-Wook" last="Hong">Kyung-Wook Hong</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Kim, In Seon" sort="Kim, In Seon" uniqKey="Kim I" first="In Seon" last="Kim">In Seon Kim</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Choi, Won Suk" sort="Choi, Won Suk" uniqKey="Choi W" first="Won Suk" last="Choi">Won Suk Choi</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author><author><name sortKey="Kim, Woo Joo" sort="Kim, Woo Joo" uniqKey="Kim W" first="Woo Joo" last="Kim">Woo Joo Kim</name><affiliation><nlm:aff id="A1">Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea.</nlm:aff></affiliation></author></analytic><series><title level="j">Clinical and Experimental Vaccine Research</title><idno type="ISSN">2287-3651</idno><idno type="eISSN">2287-366X</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose</title><p>To prepare for vaccine shortages under an influenza pandemic, several antigen-sparing strategies have been investigated. This study was aimed to evaluate the immunogenicity of influenza vaccine at reduced intradermal and full intramuscular dose.</p></sec><sec><title>Materials and Methods</title><p>We compared the effect of one-fifth and one-half intradermal doses to the full intramuscular dose on immunogenicity in healthy young adults, using a commercial influenza vaccine. A hemagglutination inhibition assay was used to compare the immunogenicity of the vaccination methods.</p></sec><sec><title>Results</title><p>The one-fifth intradermal dose (3 µg hemagglutinin antigen, HA) was given to 30 participants, the one-half intradermal dose (7.5 µg HA) was given to 30, and the full intramuscular dose (15 µg HA) was given to 32. No significant differences among injection routes and dosages were seen for seroprotection rate, seroconversion rate, or geometric mean titer (GMT) fold-increase for A/H1N1, A/H3N2, and B at around 4 weeks from vaccination. Although GMT for influenza B was significantly lower at six months for the one-fifth intradermal vaccination compared to the full-dose intramuscular vaccination (32.8 vs. 63.2, p=0.048), all three groups met the Evaluation of Medicinal Products (EMA) immunogenicity criteria through 1 to 6 months.</p></sec><sec><title>Conclusion</title><p>Intradermal administration of a one-fifth dose of influenza vaccine elicited antibody responses comparable to the intradermal one-half dose and a conventional intramuscular vaccination at 1 month post-vaccination. The immunogenicity of the one-fifth intradermal dose was sufficient to meet the requirement for the EMA criteria at six months after influenza vaccination.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Jakob, T" uniqKey="Jakob T">T Jakob</name></author><author><name sortKey="Udey, Mc" uniqKey="Udey M">MC Udey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kenney, Rt" uniqKey="Kenney R">RT Kenney</name></author><author><name sortKey="Frech, Sa" uniqKey="Frech S">SA Frech</name></author><author><name sortKey="Muenz, Lr" uniqKey="Muenz L">LR Muenz</name></author><author><name sortKey="Villar, Cp" uniqKey="Villar C">CP Villar</name></author><author><name sortKey="Glenn, Gm" uniqKey="Glenn G">GM Glenn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="La Montagne, Jr" uniqKey="La Montagne J">JR La Montagne</name></author><author><name sortKey="Fauci, As" uniqKey="Fauci A">AS Fauci</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lambert, Ph" uniqKey="Lambert P">PH Lambert</name></author><author><name sortKey="Laurent, Pe" uniqKey="Laurent P">PE Laurent</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nicolas, Jf" uniqKey="Nicolas J">JF Nicolas</name></author><author><name sortKey="Guy, B" uniqKey="Guy B">B Guy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheong, Hj" uniqKey="Cheong H">HJ Cheong</name></author><author><name sortKey="Song, Jy" uniqKey="Song J">JY Song</name></author><author><name sortKey="Park, Jw" uniqKey="Park J">JW Park</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hobson, D" uniqKey="Hobson D">D Hobson</name></author><author><name sortKey="Curry, Rl" uniqKey="Curry R">RL Curry</name></author><author><name sortKey="Beare, As" uniqKey="Beare A">AS Beare</name></author><author><name sortKey="Ward Gardner, A" uniqKey="Ward Gardner A">A Ward-Gardner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Davies, Jr" uniqKey="Davies J">JR Davies</name></author><author><name sortKey="Grilli, Ea" uniqKey="Grilli E">EA Grilli</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Koff, Rs" uniqKey="Koff R">RS Koff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Young, F" uniqKey="Young F">F Young</name></author><author><name sortKey="Marra, F" uniqKey="Marra F">F Marra</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marra, F" uniqKey="Marra F">F Marra</name></author><author><name sortKey="Young, F" uniqKey="Young F">F Young</name></author><author><name sortKey="Richardson, K" uniqKey="Richardson K">K Richardson</name></author><author><name sortKey="Marra, Ca" uniqKey="Marra C">CA Marra</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Belshe, Rb" uniqKey="Belshe R">RB Belshe</name></author><author><name sortKey="Newman, Fk" uniqKey="Newman F">FK Newman</name></author><author><name sortKey="Cannon, J" uniqKey="Cannon J">J Cannon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Auewarakul, P" uniqKey="Auewarakul P">P Auewarakul</name></author><author><name sortKey="Kositanont, U" uniqKey="Kositanont U">U Kositanont</name></author><author><name sortKey="Sornsathapornkul, P" uniqKey="Sornsathapornkul P">P Sornsathapornkul</name></author><author><name sortKey="Tothong, P" uniqKey="Tothong P">P Tothong</name></author><author><name sortKey="Kanyok, R" uniqKey="Kanyok R">R Kanyok</name></author><author><name sortKey="Thongcharoen, P" uniqKey="Thongcharoen P">P Thongcharoen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Damme, P" uniqKey="Van Damme P">P Van Damme</name></author><author><name sortKey="Oosterhuis Kafeja, F" uniqKey="Oosterhuis Kafeja F">F Oosterhuis-Kafeja</name></author><author><name sortKey="Van Der Wielen, M" uniqKey="Van Der Wielen M">M Van der Wielen</name></author><author><name sortKey="Almagor, Y" uniqKey="Almagor Y">Y Almagor</name></author><author><name sortKey="Sharon, O" uniqKey="Sharon O">O Sharon</name></author><author><name sortKey="Levin, Y" uniqKey="Levin Y">Y Levin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chuaychoo, B" uniqKey="Chuaychoo B">B Chuaychoo</name></author><author><name sortKey="Wongsurakiat, P" uniqKey="Wongsurakiat P">P Wongsurakiat</name></author><author><name sortKey="Nana, A" uniqKey="Nana A">A Nana</name></author><author><name sortKey="Kositanont, U" uniqKey="Kositanont U">U Kositanont</name></author><author><name sortKey="Maranetra, Kn" uniqKey="Maranetra K">KN Maranetra</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Belshe, Rb" uniqKey="Belshe R">RB Belshe</name></author><author><name sortKey="Newman, Fk" uniqKey="Newman F">FK Newman</name></author><author><name sortKey="Wilkins, K" uniqKey="Wilkins K">K Wilkins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beran, J" uniqKey="Beran J">J Beran</name></author><author><name sortKey="Ambrozaitis, A" uniqKey="Ambrozaitis A">A Ambrozaitis</name></author><author><name sortKey="Laiskonis, A" uniqKey="Laiskonis A">A Laiskonis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arnou, R" uniqKey="Arnou R">R Arnou</name></author><author><name sortKey="Eavis, P" uniqKey="Eavis P">P Eavis</name></author><author><name sortKey="Pardo, Jr" uniqKey="Pardo J">JR Pardo</name></author><author><name sortKey="Ambrozaitis, A" uniqKey="Ambrozaitis A">A Ambrozaitis</name></author><author><name sortKey="Kazek, Mp" uniqKey="Kazek M">MP Kazek</name></author><author><name sortKey="Weber, F" uniqKey="Weber F">F Weber</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chi, Rc" uniqKey="Chi R">RC Chi</name></author><author><name sortKey="Rock, Mt" uniqKey="Rock M">MT Rock</name></author><author><name sortKey="Neuzil, Km" uniqKey="Neuzil K">KM Neuzil</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leroux Roels, I" uniqKey="Leroux Roels I">I Leroux-Roels</name></author><author><name sortKey="Vets, E" uniqKey="Vets E">E Vets</name></author><author><name sortKey="Freese, R" uniqKey="Freese R">R Freese</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Campos Outcalt, D" uniqKey="Campos Outcalt D">D Campos-Outcalt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ansaldi, F" uniqKey="Ansaldi F">F Ansaldi</name></author><author><name sortKey="De Florentiis, D" uniqKey="De Florentiis D">D de Florentiis</name></author><author><name sortKey="Durando, P" uniqKey="Durando P">P Durando</name></author><author><name sortKey="Icardi, G" uniqKey="Icardi G">G Icardi</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Exp Vaccine Res</journal-id><journal-id journal-id-type="iso-abbrev">Clin Exp Vaccine Res</journal-id><journal-id journal-id-type="publisher-id">CEVR</journal-id><journal-title-group><journal-title>Clinical and Experimental Vaccine Research</journal-title></journal-title-group><issn pub-type="ppub">2287-3651</issn><issn pub-type="epub">2287-366X</issn><publisher><publisher-name>The Korean Vaccine Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23858402</article-id><article-id pub-id-type="pmc">3710919</article-id><article-id pub-id-type="doi">10.7774/cevr.2013.2.2.115</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Song</surname><given-names>Joon Young</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cheong</surname><given-names>Hee Jin</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Noh</surname><given-names>Ji Yun</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Tae Un</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Seo</surname><given-names>Yu Bin</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Kyung-Wook</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>In Seon</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Won Suk</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Woo Joo</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</aff><aff id="A2"><label>2</label>Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea.</aff><author-notes><corresp>Corresponding author: Hee Jin Cheong, MD, PhD. Division of Infectious Disease, Department of Internal Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul 152-703, Korea. Tel: +82-2-2626-3050, Fax: +82-2-2626-1105, <email>heejinmd@medimail.co.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>03</day><month>7</month><year>2013</year></pub-date><volume>2</volume><issue>2</issue><fpage>115</fpage><lpage>119</lpage><history><date date-type="received"><day>21</day><month>3</month><year>2013</year></date><date date-type="rev-recd"><day>31</day><month>3</month><year>2013</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>© Korean Vaccine Society.</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To prepare for vaccine shortages under an influenza pandemic, several antigen-sparing strategies have been investigated. This study was aimed to evaluate the immunogenicity of influenza vaccine at reduced intradermal and full intramuscular dose.</p></sec><sec><title>Materials and Methods</title><p>We compared the effect of one-fifth and one-half intradermal doses to the full intramuscular dose on immunogenicity in healthy young adults, using a commercial influenza vaccine. A hemagglutination inhibition assay was used to compare the immunogenicity of the vaccination methods.</p></sec><sec><title>Results</title><p>The one-fifth intradermal dose (3 µg hemagglutinin antigen, HA) was given to 30 participants, the one-half intradermal dose (7.5 µg HA) was given to 30, and the full intramuscular dose (15 µg HA) was given to 32. No significant differences among injection routes and dosages were seen for seroprotection rate, seroconversion rate, or geometric mean titer (GMT) fold-increase for A/H1N1, A/H3N2, and B at around 4 weeks from vaccination. Although GMT for influenza B was significantly lower at six months for the one-fifth intradermal vaccination compared to the full-dose intramuscular vaccination (32.8 vs. 63.2, p=0.048), all three groups met the Evaluation of Medicinal Products (EMA) immunogenicity criteria through 1 to 6 months.</p></sec><sec><title>Conclusion</title><p>Intradermal administration of a one-fifth dose of influenza vaccine elicited antibody responses comparable to the intradermal one-half dose and a conventional intramuscular vaccination at 1 month post-vaccination. The immunogenicity of the one-fifth intradermal dose was sufficient to meet the requirement for the EMA criteria at six months after influenza vaccination.</p></sec></abstract><kwd-group><kwd>Vaccines</kwd><kwd>Influenza vaccines</kwd><kwd>Immunogenicity</kwd><kwd>Intradermal injections</kwd><kwd>Adult</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Influenza is one of the most common infectious diseases, with global epidemics occurring every 10-40 years. Although relatively benign, influenza can be associated with significant morbidity and mortality; influenza-related complications include pneumonia, encephalitis, myocarditis, and gradual deterioration of organ functions. Annual vaccination is the primary measure for preventing influenza-related morbidity and mortality, but the vaccine supply can be limited in an early pandemic situation. To prepare for potential vaccine shortages under an influenza pandemic, several antigen-sparing strategies have been investigated. These include adjuvanted vaccines and new methods of administering vaccines such as intradermal and subcutaneous injection.</p><p>Intradermal influenza vaccination requires less antigen to be as effective as regular intramuscular vaccination. The improved immune response is due to the higher level of dendritic cells in the dermis than in the muscle [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Furthermore, the dermis has a rich supply of blood and lymphatic vessels that aids circulation of immune cells [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>In this study, we compared the long-term immunogenicity of intradermal vaccination at one-fifth and one-half doses to full-dose intramuscular vaccination of a commercial influenza vaccine in healthy young adults.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Vaccine and study design</title><p>During the 2006-2007 influenza season, we compared the long-term immunogenicity in healthy young adults of an intradermal influenza vaccination at one-fifth and one-half the conventional antigenic contents with an intramuscular vaccination at the conventional dose (<xref ref-type="fig" rid="F1">Fig. 1</xref>). We randomly assigned 96 participants in a 1:1:1 ratio to three vaccination groups: intradermal one-fifth dose (0.1 mL, 3 µg hemagglutinin antigen [HA]/strain), intradermal one-half (0.25 mL, 7.5 µg HA/strain), and intramuscular full-dose (0.5 mL, 15 µg HA/strain). Serum hemagglutinin inhibition (HI) antibody titers were determined for recommended influenza strains pre-vaccination and at one and six months after vaccination.</p><p>The trivalent inactivated split vaccine (Influenza HA vaccine, Green Cross, Yongin, Korea), containing 15 µg HA/strain per 0.5 mL dose, was used. The vaccine contained the following influenza strains: A/New Caledonia/20/99 (H1N1)-like virus, A/Wisconsin/67/2005 (H3N2)-like virus, and B/Malaysia/2506/2004-like virus.</p><p>Subjects enrolled in the study were healthy young adults aged 18-30 years. Exclusion criteria included immunosuppressant use, hypersensitivity to any vaccine component (including eggs), or a history of Guillain-Barre syndrome. Other exclusion criteria included thrombocytopenia, any coagulation disorder contraindicating intramuscular injection, or current febrile illness or another acute illness. Anyone who received gamma globulin during the previous three months or any other vaccination within the past 30 days was excluded.</p><p>The study was approved by the ethics committee of Korea University Guro Hospital (IRB No. KUGH0691) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All participants provided written, informed consent before enrollment. Venous blood samples of 10 mL were taken on day 0, post-vaccination day 30±7, and post-vaccination day 180±7.</p></sec><sec><title>HI assay</title><p>Standard microtiter HI assays was performed as previously described [<xref ref-type="bibr" rid="B6">6</xref>]. A titer of ≥1:40 was considered a protective level [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Geometric mean titer (GMT) was determined pre-vaccination and at 1 month and 6 months post-vaccination. Serologic response, measured by HI antibody titer, was assessed using the criteria of the Evaluation of Medicinal Products (EMA) [<xref ref-type="bibr" rid="B9">9</xref>]. To confirm protective immunogenicity, at least one of the following three criteria were required for each influenza virus strain: 1) GMT-fold increase >2.5-fold, 2) Seroprotection rate >70%, and 3) Seroconversion rate >40%.</p></sec><sec><title>Statistical analysis</title><p>All statistical analysis was by SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics are reported as number of participants and corresponding percentage. HI antibody titers are expressed as geometric mean with 95% confidence interval. Analysis of variance (ANOVA) was used to assess variation of GMTs among groups for each time point; multiple comparison tests were based on Turkey's method. Categorical variables were analyzed using chi-square test (Fisher's exact test for less than 30 samples). Statistical significance was signified by a p-value less than 0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Among 96 enrolled participants, 4 were dropped from the study because of declining serum sampling. The experimental groups were comprised of 30, 30, and 32 participants in the intradermal one-fifth dose (0.1 mL, 3 µg HA), intradermal one-half dose (0.25 mL, 7.5 µg HA), and intramuscular full-dose (0.5 mL, 15 µg HA) groups, respectively. Baseline demographic characteristics of patients are in <xref ref-type="table" rid="T1">Table 1</xref>. No remarkable differences were observed between the groups.</p><p>All three groups met the EMA immunogenicity criteria in the 1-6 month study period (<xref ref-type="table" rid="T2">Table 2</xref>). For influenza A/H1N1 virus, the seroprotection (titer≥1:40) rates for the groups were 80.0% for the one-fifth dose, 90.0% for the one-half dose, and 87.5% for the full dose. For A/H3N2 virus, rates were 70.0% for the one-fifth dose, 90.0% for the one-half dose, and 84.4% for the full dose. For influenza B virus, rates were 60.0%, 60.0%, and 71.9%. No significant intergroup differences were observed at 1 month or 6 months post-vaccination (<xref ref-type="table" rid="T2">Table 2</xref>). GMTs increased by >2.5 in the 1-6 months for all 3 strains irrespective of injection route or dosage (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Seroconversion rates were above 40% for all three strains at 1 month post-vaccination, but the rate for influenza B declined to less than 40% at 6 months for the one-fifth dose vaccination (<xref ref-type="table" rid="T2">Table 2</xref>). GMT for influenza B was significantly lower at 6 months after the one-fifth intradermal dose compared to the full-dose intramuscular vaccination: 32.8 vs. 63.2 (p=0.048) (<xref ref-type="table" rid="T2">Table 2</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>This study showed that the immunogenicity of one-fifth and one-half doses of intradermal seasonal influenza vaccine were largely comparable to full-dose intramuscular vaccination in healthy young adults. All three groups satisfied the EMA immunogenicity criteria for influenza vaccines, although the intradermal one-fifth dose vaccination elicited lower antibody responses than the intradermal one-half dose and the conventional dose of an intramuscular vaccination. Intramuscular vaccination bypasses the skin's immune system, while intradermal vaccination targets dense populations of dendritic cells in the skin. Skin is considered a desirable target for vaccination; about 25% of the skin is covered by dendritic cells, which are postulated to acquire antigens in peripheral tissue by priming naive T cells [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Moreover, antigen is suggested to become trapped in the cutaneous tissue for long periods after intradermal injection, compared to intramuscular injection [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Several trials of intradermal influenza vaccines have studied the characteristic features of the dermal immune system in adults of diverse ages [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. A recent literature review [<xref ref-type="bibr" rid="B11">11</xref>] found 10 trials using reduced-dose intradermal influenza vaccines ranging from 3 to 9 µg HA per strain. Among these trials, five used a 3-µg dose [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. Of the 10 trials, 8 found comparable responses between intradermal influenza vaccines at a reduced dose and a full-dose intramuscular vaccine [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. One trial showed that a dose-sparing intradermal vaccine was superior to a conventional-dose intramuscular vaccine [<xref ref-type="bibr" rid="B21">21</xref>]. Thus, intradermal influenza vaccines at a reduced dose can be immunogenic in a way that is comparable to a full-dose intramuscular vaccine. However, data on antibody persistence has been insufficient. In this study, we showed that even a one-fifth dose of an intradermal vaccine induced antibody responses that persisted for six months.</p><p>This study has some limitations. First, we did not include elderly people, so long-term immunogenicity needs to be investigated among this population. Second, cross-reactive immunogenicity against drifted strains was not evaluated. Third, the history of influenza infections in the previous year was not considered.</p><p>Recently, the United States expanded the recommendation of influenza vaccination to children and adults without high-risk conditions [<xref ref-type="bibr" rid="B22">22</xref>]. In addition to these increased requirements, we experienced vaccine shortages during the 2009 influenza pandemic, and the United States suffered from vaccine shortages from the contamination of a vaccine-producing plant during the 2004-2005 season [<xref ref-type="bibr" rid="B23">23</xref>]. Thus, dose-sparing intradermal vaccines might be an effective strategy for preparation for an influenza pandemic, and could also be useful during interpandemic periods.</p></sec></body><back><fn-group><fn fn-type="conflict"><p>No potential conflict of interest relevant to this article was reported.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakob</surname><given-names>T</given-names></name><name><surname>Udey</surname><given-names>MC</given-names></name></person-group><article-title>Epidermal Langerhans cells: from neurons to nature's adjuvants</article-title><source>Adv Dermatol</source><year>1999</year><volume>14</volume><fpage>209</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">10643500</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenney</surname><given-names>RT</given-names></name><name><surname>Frech</surname><given-names>SA</given-names></name><name><surname>Muenz</surname><given-names>LR</given-names></name><name><surname>Villar</surname><given-names>CP</given-names></name><name><surname>Glenn</surname><given-names>GM</given-names></name></person-group><article-title>Dose sparing with intradermal injection of influenza vaccine</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>2295</fpage><lpage>2301</lpage><pub-id pub-id-type="pmid">15525714</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Montagne</surname><given-names>JR</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name></person-group><article-title>Intradermal influenza vaccination: can less be more?</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>2330</fpage><lpage>2332</lpage><pub-id pub-id-type="pmid">15525715</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>PH</given-names></name><name><surname>Laurent</surname><given-names>PE</given-names></name></person-group><article-title>Intradermal vaccine delivery: will new delivery systems transform vaccine administration?</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>3197</fpage><lpage>3208</lpage><pub-id pub-id-type="pmid">18486285</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolas</surname><given-names>JF</given-names></name><name><surname>Guy</surname><given-names>B</given-names></name></person-group><article-title>Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice</article-title><source>Expert Rev Vaccines</source><year>2008</year><volume>7</volume><fpage>1201</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">18844594</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheong</surname><given-names>HJ</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><etal></etal></person-group><article-title>Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>2417</fpage><lpage>2422</lpage><pub-id pub-id-type="pmid">16406176</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobson</surname><given-names>D</given-names></name><name><surname>Curry</surname><given-names>RL</given-names></name><name><surname>Beare</surname><given-names>AS</given-names></name><name><surname>Ward-Gardner</surname><given-names>A</given-names></name></person-group><article-title>The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses</article-title><source>J Hyg (Lond)</source><year>1972</year><volume>70</volume><fpage>767</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">4509641</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>JR</given-names></name><name><surname>Grilli</surname><given-names>EA</given-names></name></person-group><article-title>Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses</article-title><source>Epidemiol Infect</source><year>1989</year><volume>102</volume><fpage>325</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">2703026</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="book"><collab>European Committee for Proprietary Medicinal Products</collab><source>Note for guidance on harmonisation of requirements for influenza vaccines</source><publisher-loc>London</publisher-loc><publisher-name>The Europen Agency for the Evaluation of Medicinal Products</publisher-name><year>1997</year></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koff</surname><given-names>RS</given-names></name></person-group><article-title>Immunogenicity of hepatitis B vaccines: implications of immune memory</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>3695</fpage><lpage>3701</lpage><pub-id pub-id-type="pmid">12399197</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>F</given-names></name><name><surname>Marra</surname><given-names>F</given-names></name></person-group><article-title>A systematic review of intradermal influenza vaccines</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>8788</fpage><lpage>8801</lpage><pub-id pub-id-type="pmid">21968444</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marra</surname><given-names>F</given-names></name><name><surname>Young</surname><given-names>F</given-names></name><name><surname>Richardson</surname><given-names>K</given-names></name><name><surname>Marra</surname><given-names>CA</given-names></name></person-group><article-title>A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events</article-title><source>Influenza Other Respi Viruses</source><year>2013</year><volume>7</volume><fpage>584</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">22974174</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belshe</surname><given-names>RB</given-names></name><name><surname>Newman</surname><given-names>FK</given-names></name><name><surname>Cannon</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Serum antibody responses after intradermal vaccination against influenza</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>2286</fpage><lpage>2294</lpage><pub-id pub-id-type="pmid">15525713</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auewarakul</surname><given-names>P</given-names></name><name><surname>Kositanont</surname><given-names>U</given-names></name><name><surname>Sornsathapornkul</surname><given-names>P</given-names></name><name><surname>Tothong</surname><given-names>P</given-names></name><name><surname>Kanyok</surname><given-names>R</given-names></name><name><surname>Thongcharoen</surname><given-names>P</given-names></name></person-group><article-title>Antibody responses after dose-sparing intradermal influenza vaccination</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>659</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">17011678</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Oosterhuis-Kafeja</surname><given-names>F</given-names></name><name><surname>Van der Wielen</surname><given-names>M</given-names></name><name><surname>Almagor</surname><given-names>Y</given-names></name><name><surname>Sharon</surname><given-names>O</given-names></name><name><surname>Levin</surname><given-names>Y</given-names></name></person-group><article-title>Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>454</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">19022318</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuaychoo</surname><given-names>B</given-names></name><name><surname>Wongsurakiat</surname><given-names>P</given-names></name><name><surname>Nana</surname><given-names>A</given-names></name><name><surname>Kositanont</surname><given-names>U</given-names></name><name><surname>Maranetra</surname><given-names>KN</given-names></name></person-group><article-title>The immunogenicity of intradermal influenza vaccination in COPD patients</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>4045</fpage><lpage>4051</lpage><pub-id pub-id-type="pmid">20412877</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belshe</surname><given-names>RB</given-names></name><name><surname>Newman</surname><given-names>FK</given-names></name><name><surname>Wilkins</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>6755</fpage><lpage>6763</lpage><pub-id pub-id-type="pmid">17692438</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beran</surname><given-names>J</given-names></name><name><surname>Ambrozaitis</surname><given-names>A</given-names></name><name><surname>Laiskonis</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial</article-title><source>BMC Med</source><year>2009</year><volume>7</volume><fpage>13</fpage><pub-id pub-id-type="pmid">19341446</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnou</surname><given-names>R</given-names></name><name><surname>Eavis</surname><given-names>P</given-names></name><name><surname>Pardo</surname><given-names>JR</given-names></name><name><surname>Ambrozaitis</surname><given-names>A</given-names></name><name><surname>Kazek</surname><given-names>MP</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name></person-group><article-title>Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: randomized, controlled, phase III trial</article-title><source>Hum Vaccin</source><year>2010</year><volume>6</volume><fpage>346</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">20372053</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>RC</given-names></name><name><surname>Rock</surname><given-names>MT</given-names></name><name><surname>Neuzil</surname><given-names>KM</given-names></name></person-group><article-title>Immunogenicity and safety of intradermal influenza vaccination in healthy older adults</article-title><source>Clin Infect Dis</source><year>2010</year><volume>50</volume><fpage>1331</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">20377407</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leroux-Roels</surname><given-names>I</given-names></name><name><surname>Vets</surname><given-names>E</given-names></name><name><surname>Freese</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>6614</fpage><lpage>6619</lpage><pub-id pub-id-type="pmid">18930093</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos-Outcalt</surname><given-names>D</given-names></name></person-group><article-title>CDC recommendations expand vaccine indications</article-title><source>J Fam Pract</source><year>2009</year><volume>58</volume><fpage>146</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">19284941</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansaldi</surname><given-names>F</given-names></name><name><surname>de Florentiis</surname><given-names>D</given-names></name><name><surname>Durando</surname><given-names>P</given-names></name><name><surname>Icardi</surname><given-names>G</given-names></name></person-group><article-title>Fluzone((R)) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults</article-title><source>Expert Rev Vaccines</source><year>2012</year><volume>11</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">22149703</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>A total of 96 healthy adults were enrolled in the study and assigned to one of three vaccination regimens, receiving intradermal (ID) one-fifth dose (0.1 mL, 3 ±g hemagglutinin antigen [HA]), ID one-half dose (0.25 mL, 7.5 ±g HA) or intramuscular (IM) full-dose (0.5 mL, 15 ±g HA) vaccination. Immunogenicity was assessed up to six months after vaccination. F/U, follow-up.</p></caption><graphic xlink:href="cevr-2-115-g001"></graphic></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Geometric mean titer (GMT) fold-increases were assessed at 1 month post-vaccination (A) and 6 months post-vaccination (B), by hemagglutination inhibition assay.</p></caption><graphic xlink:href="cevr-2-115-g002"></graphic></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of study subjects</p></caption><graphic xlink:href="cevr-2-115-i001"></graphic><table-wrap-foot><fn><p>Values are presented as mean±SD or n (%).</p><p>SD, standard deviation; BMI, body mass index.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Comparison of short- and long-term immune responses after influenza vaccination, by hemagglutination inhibition assay</p></caption><graphic xlink:href="cevr-2-115-i002"></graphic><table-wrap-foot><fn><p>The same letters indicate non-significant differences between groups based on Tukey's multiple comparison tests.</p><p>The numbers in parentheses represent 95% confidence interval.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000975 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000975 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3710919
|texte= Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23858402" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |